Objective: Previous studies have shown that half of the spontaneous abortions were associated with fetal chromosomal abnormalities, however it is not always possible to reveal the reasons of pregnancy loss. The aim of the current study was to investigate the frequency of chromosome abnormalities and culture failure rates of pregnancy loss and compare the results with similar studies in the literature. Material and Methods: The karyotype analysis results of 1208 abortion materials which were obtained from long-term cultures of chorionic villus samples of the patients who were admitted to the Haseki Training and Research Hospital Genetic Diagnosis Center between August 2016 and February 2021, were evaluated retrospectively. Results: No results were obtained due to culture failure in approximately half of the materials. Numerical anomalies were observed in 87% (116) of abnormal karyotypes that consist of trisomy, monosomy X and triploidy. Trisomies were the most common anomaly. While the frequency of trisomy was significantly higher in the older age group (≥35 years) (p=0.001), the frequency of monosomy X and triploidy were higher in the younger age group. Chromosomal changes whose frequencies were not affected by maternal age were structural chromosomal abnormalities and tetraploidies. Conclusion: Since the developing new Technologies are still not affordable enough and their widespread use is limited. As a result, current approaches have indicated that chromosome analysis is still a necessary and useful method. It is thought that detecting the chromosomal anomaly that led to abortion facilitates multidisciplinary patient management and enables to provide more accurate and comprehensive genetic counseling. In cases where the chromosome analysis test is not informative, the application of DNA-based tests such as Quantitative Fluorescence PCR (QF-PCR) and molecular karyotyping may help the diagnosis.
Duchenne Muscular Dystrophy (DMD) is the most prevalent muscle disease in children, and unfortunately, currently there are no effective treatments for either DMD or Becker Muscular Dystrophy (BMD). Nevertheless, targeted gene therapy treatments have recently emerged, and genetic diagnoses is now the basis of treatment. In addition, genetic and prenatal diagnosis have significantly reduced the incidence rates of these diseases. The aim of this study was to identify the most common deletion and duplication regions in the Turkish population using the Multiplex Ligation-dependent Probe Amplification (MLPA) method, as well as to determine the suitability of patients for current treatments and identify new treatment target regions based on the findings. In clinical practice, data from 103 patients with Duchenne and Becker muscular dystrophy who have been identified with the deletion/duplication using the Multiplex Ligation-dependent Probe Amplification (MLPA) method, as well as 35 participants carrying the deletion/duplication for these diseases, were analyzed. The aim was to detect the most common deletion/duplication regions of the Dystrophin gene in the Turkish population. The majority of patients had deletions (89.9% in males and 75% in females), while a smaller percentage had duplications. The most common deletions occurred in exons 50 and 49, while the most common duplication was in exon 7. The deletions in exons 45-52 accounted for over half of all deletions, and most deletions involved 5 or less exons. The longest deletions involved 30 exons and were found in 2 patients. The findings of this research have provided valuable insights into the prevalence of deletions and duplications in the dystrophin gene among individuals in our population. The results indicate that a significant proportion of patients may be eligible for treatments that are not yet widely available. This study highlights the critical role of population-specific data in advancing the field of dystrophin gene-based therapies.
24 December 2024 in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
Objective: Detection of copy number variations (CNVs) through molecular karyotyping is a useful method to assess the genetic anomalies with dysmorphic features and multiple congenital anomalies. This study demonstrated the diagnostic rate of chromosomal microarray analysis in patients with specific phenotype, and also contributed the literature with presenting new patients with very rare CNVs. Material and Methods: Chromosomal microarray analysis was performed in 419 patients with dysmorphic features and multiple congenital anomalies. Results: A total of 61 CNVs were detected in 50 patients (12%). Two of these patients exhibited a 2q33.1 deletion. While patient 13 presented with speech delay, seizures, behavioral abnormalities, and a 469 kbp deletion disrupting SATB2, patient 14 displayed immune deficiency, failure to thrive, hypothyroidism, diarrhea, cryptorchidism, and ectodermal features such as alopecia, nail dysplasia, and oligodontia. This patient had a 7.5 Mb deletion on 2q33.1q34, which included CTLA4 and was responsible for the immune deficiency symptoms of the patient. The CASP10, was not included in the deletion region. Conclusions: According to our study, co-deletion of CTLA4 and CASP10 did not lead to phenotypic effects like immune deficiency. Rather, only the deletion of the CTLA4 gene may result in hypogammaglobulinemia and immune deficiency. These findings suggest that chromosomal microarray analysis can be a valuable tool in diagnosing rare CNVs and guiding clinical management, particularly in patients with immune deficiency and other congenital anomalies. Identifying specific gene deletions, such as CTLA4, may inform personalized treatment approaches, including immune-modulating therapies, and provide insights for genetic counseling in affected families.